Bionano Shares Overview of AGBT Pre-Conference Workshop Program Along with Details of Company’s Innovative Research Grant Opportunity
- Bionano leaders presented on the ability of optical genome mapping (OGM) to potentially replace traditional cytogenetic methods for structural variant (SV) detection and shared details of the company’s new product advancements
- Bionano and NVIDIA previewed their collaborative development, a new compute solution for OGM analysis
- Dr. Alexander Hoischen,
Radboud Genomics Technology Center, presented on his experience using OGM as a replacement for traditional cytogenetic methods of genome analysis and shared case studies showing OGM’s ability to identify previously undetected SVs relevant to rare disease Dr. Adam Smith, University Health Network, University of Toronto, presented on his use of VIA™, Bionano’s new software solution (currently in limited release), for data filtering and analysis in hematologic research
- Bionano announced a grant opportunity designed to fuel translational research across a number of novel research areas using OGM
- On-demand webcast from the AGBT workshop is available on the company’s website
Bionano and collaborators outlined advances to Bionano’s digital workflow, which can provide SV detection relevant to clinical and translational research in areas including cancer and genetic disease with greater resolution and sensitivity than traditional cytogenetic methods.
- Bionano announced product advancements that can enable higher throughput, improve data analysis and reporting, and improve DNA isolation and extraction: Presenters described upcoming product improvements, including the anticipated launches of the Ionic® system for OGM applications, the high throughput Saphyr® system, the expansion of Bionano’s sample prep menu, and improved analysis and reporting software. The presentation from Bionano and NVIDIA introduced Bionano’s new compute solution with increased data processing capabilities, which was co-developed to support higher throughput OGM instruments.
- Bionano’s OGM solutions and VIA software can offer clinical and translational researchers genome analysis with high resolution and sensitivity, a simple workflow, and improved turnaround times: At the event, Dr. Hoischen described how his research shows that OGM can identify more hidden or missed SVs relevant to rare disease than traditional methods.
Dr. Smithnoted VIA’s ability to provide analysis and reporting of SVs in a simple report with improved classification and filtering of SVs when compared to other reporting software.
- Bionano launched a grant opportunity designed to further transformational research involving SVs using OGM technology:
Dr. Purimshared details of Bionano’s new grant program, which will award five prizes to researchers across a variety of research areas. Grant applications are now open and will close in May 2023.
“Bionano was pleased to sponsor the pre-conference workshop at AGBT, where we shared product development plans, news about our strategic collaboration with NVIDIA and an announcement of our Bionano Innovator Research Grant. We were also excited to include Drs. Smith and Hoischen in our program, where they presented details of innovative research and data analysis they have conducted utilizing Bionano technology. AGBT is where people come together to talk about significant advances in genomic technology, and we were thrilled to provide conference attendees with an overview of the improvements we are making to OGM offerings,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics.
A live webcast of the workshop is available here: https://bionano.com/agbt2023/ More details about the Bionano Innovator Research Grant opportunity can be found here: www.bionano.com/innovatorgrant
Research areas for consideration include:
Bionano’s products are for research use only. Not for use in diagnostic procedures.
Forward-Looking Statements of
This press release contains forward-looking statements contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can,” “plan," “anticipate,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances and the negatives thereof) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: (1) the impact and utility of optical genome mapping (OGM) in cancer and genetic disease research, and expected improvements to OGM over time; (2) the ability and utility of OGM to be complementary to, or used in lieu of, traditional cytogenomics methods for analysis of structural variations; (3) the utility and ability of the VIA software to provide genome analysis with high resolution and sensitivity, a simple workflow, and improved turnaround times; (4) the utility and ability of our new compute solution with increased data processing capabilities, which was co-developed to support higher throughput OGM instruments; (5) improved turnaround times our ability to stay in front of competitors' improvements in technologies; (6) the anticipated benefits and ultimate success of our collaborations; (7) our future products and features; and (8) other statements that are not historical facts.
Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: (1) the impact of geopolitical and macroeconomic developments, such as the ongoing
+1 (858) 888-7610
+1 (858) 366-3243
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/965c4b2e-d363-40d1-9d59-1f9f8a5e0365
Source: Bionano Genomics